Enzymatica AB: Extraordinary shareholders' meeting on changes to the board of directors
December 01 2016 - 2:30AM
Press release
Lund, 1 December 2016
Enzymatica: Extraordinary
shareholders' meeting on changes to the board of directors
The board of directors of
Enzymatica has resolved to convene an extraordinary shareholders'
meeting to be held on 19 December 2016 regarding changes to the
composition of the board of directors. Bengt Baron is proposed as
new chairman of Enzymatica and Mats K Andersson and Louise Nicolin
as new board members. A notice convening the extraordinary
shareholders' meeting is to be distributed within short. The
company has been informed that shareholders representing more than
50 per cent of the shares and votes of Enzymatica support the
proposal.
The background of the resolution by the board of
directors to convene an extraordinary shareholders' meeting is that
the new large shareholders of Enzymatica wish to have influence on
the company's operations and that the board of directors represents
the new shareholder structure in a more appropriate manner. The
company has been informed that Gudmundur Palmason and Sigurgeir
Gudlaugsson with families (directly and indirectly through
companies), Mats K Andersson (directly and indirectly through
companies), Fibonacci Asset Management AB and RoosGruppen AB are
supporting the proposal. These investors became shareholders
earlier this year in connection with Enzymatica's acquisition of
the Icelandic company Zymetech and through the implementation of
two new share issues, which provided Enzymatica with a capital
contribution of approximately MSEK 100 before issue expenses. At
the same time, it has been Lennart Nilsson's (Enzymatica's present
chairman) wish, after the acquisition of Zymetech and the new share
issues, to hand over the chairmanship to somebody who can follow
the company during a longer period.
The proposal entails that the company's board of
directors will consist of six ordinary board members compared to
today's seven board members, that the board members Lennart
Nilsson, Hans Pihl, Nils Siegbahn and Monica Wallter will leave the
board of directors and that Bengt Baron, Mats K Andersson and
Louise Nicolin will be appointed as new board members up to and
including the next annual general meeting. Marianne Dicander
Alexandersson, Gudmundur Palmason and Sigurgeir Gudlaugsson remain
as board members. Bengt Baron is proposed chairman of the board of
directors.
Bengt Baron
Born 1962. BSc in Business Administration and MBA from University
of California, Berkeley. Bengt currently has appointments as
chairman of the board in MIPS AB and as board member in Thule Group
AB (publ) and 5653 Sweden AB. Bengt has previously been CEO of
Cloetta AB and Leaf International B.V. Holdings: No shares in the
company.
Mats K Andersson
Born 1955. Education in International Economics from Lund
University. Mats currently has appointments as chairman of the
board in Lomond Invest AB, Abanico Invest AB and Andersson & Co
AB, and as board member in Volati Parts AB and Hills Golf AB. Mats
has previously been CEO at Lomond Industrier AB and Business Unit
Manager and deputy CEO at LICare AB (publ). Holdings: 11,346,951
shares in the company (directly and indirectly through
companies).
Louise Nicolin
Born 1973. MSc in Molecular Biotechnology from Uppsala University.
Exc. MBA from Stockholm School of Business. Louise currently has
appointments as chairman of the board in Better Business World Wide
and as board member in Volati AB (publ), VBG Group AB (publ),
Uppdragshuset Sverige AB and board assignments within Dellner
Couplers AB. Louise is since year 2000 running a consultant
business in Nicolin Consulting AB with focus on business
development and quality assurance, and has previously been Business
Unit Manager and Consultant Manager at PlantVision AB.
Holdings: No shares in the company.
For
more information, please contact:
Lennart Nilsson, Styrelseordförande Enzymatica
AB
Tel: +46 705-12 32 95 | E-post: lennart.nilsson@crafoord.se
This information is information
that Enzymatica AB (publ) is obliged to make public pursuant to the
EU Market Abuse Regulation. The information was submitted for
publication, through the agency of the contact person set out
above, at 08.30 AM CET on 1 December 2016.
About Enzymatica AB
Enzymatica is a life science company who develops and sells medical
device products against infectious-related diseases. Over a short
period the company has developed a unique oral spray for colds,
ColdZyme®, and launched it on six markets. The product has become
one of the leading articles for colds in Swedish pharmacies.
Enzymatica's strategy is to continue growing by strengthening its
position in existing markets and to expand to more geographical
markets through well-established partners. The company is
headquartered in Lund, Sweden and is listed on Nasdaq First North.
For more information, please visit www.enzymatica.com.
Enzymatica's Certified Adviser is Erik Penser
Bankaktiebolag.
Press Release Enzymatica changes in
the board of directors
This
announcement is distributed by Nasdaq Corporate Solutions on behalf
of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely
responsible for the content, accuracy and originality of the
information contained therein.
Source: Enzymatica AB via Globenewswire
ENZYMOTEC LTD. (NASDAQ:ENZY)
Historical Stock Chart
From Jun 2024 to Jul 2024
ENZYMOTEC LTD. (NASDAQ:ENZY)
Historical Stock Chart
From Jul 2023 to Jul 2024